Insider · CIK 0001693858
James Rolke
Files at REVB (REVELATION BIOSCIENCES, INC.). First filing -, latest -.
In brief
James Rolke files SEC Form 4 as CEO and director at REVB (REVELATION BIOSCIENCES, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Rolke has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | REVB REVELATION BIOSCIENCES, INC. | AGrant or award Common Stock | +208,076 | $0.00 | $0 | 422,814 | Aug 18, 2026 |
| Apr 30, 2026 | REVB REVELATION BIOSCIENCES, INC. | FTax withholding Common Stock | -10,115 | $1.13 | $11k | 214,738 | May 1, 2026 |
| Feb 3, 2026 | REVB REVELATION BIOSCIENCES, INC. | FTax withholding Common Stock | -8,521 | $1.86 | $16k | 224,853 | Feb 5, 2026 |
| Jan 8, 2026 | REVB REVELATION BIOSCIENCES, INC. | AGrant or award Common Stock | +532,829 | $0.90 | $480k | 933,489 | Jan 12, 2026 |
| Oct 29, 2025 | REVB REVELATION BIOSCIENCES, INC. | AGrant or award Common Stock | +390,614 | $1.28 | $500k | 400,660 | Oct 31, 2025 |
Questions about James Rolke
Answered from the filings on this page, as of the latest one.
Is James Rolke buying or selling?
James Rolke has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Rolke's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Rolke has 0.
Where does James Rolke file Form 4?
James Rolke has filed Form 4 at REVB (REVELATION BIOSCIENCES, INC.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.